NIH / UG1, Blood and Marrow Transplant Clinical Research Network Competitive Renewal, Krishnan (Co-I)

NIH / R01, Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma, Y. Chen and Krishnan

Amyloidosis Foundation, CS1 Chimeric Antigen Receptor Adoptive T Cell Therapy for Light Chain Amyloidosis, Rosenzweig

Multiple Myeloma Research Fund (MMRF), Combination Immunotherapy for Multiple Myeloma with CAR T cells and IMiDs, Htut

NIH / R01, SUMO Modification and Cancer Therapy, Y. Chen

NIH / R01, Reolysin-based combination therapy in relapsed multiple myeloma, Pichiorri

NIH / R01, Overcoming IMiD resistance in Myeloma, Pichiorri

MMRF, 2017 Site Investment Grant, Krishnan

City of Hope – UC Riverside Biomedical Research Initiative (CUBRI), Novel potent and selective XIAP antagonists for the treatment of Multiple Myeloma (MM), Pichiorri